Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C
- 20 October 2001
- Vol. 323 (7318) , 923-926
- https://doi.org/10.1136/bmj.323.7318.923
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Evidence based policy: proceed with care Commentary: research must be taken seriouslyBMJ, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Consequences of discharges from intensive care at nightThe Lancet, 2000
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000
- Threats to Applicability of Randomised Trials: Exclusions and Selective ParticipationJournal of Health Services Research & Policy, 1999
- Understanding controlled trials: What are pragmatic trials?BMJ, 1998
- Why we need observational studies to evaluate the effectiveness of health careBMJ, 1996
- Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklistsControlled Clinical Trials, 1995
- Science of urinary incontinenceThe Lancet, 1994
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992